DIMERIX LIMITED

0.88%

56.0¢

Market Cap $327.6M

Healthcare Biotechnology

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Latest Threads

Tag

Subject

DXB

Ann: Application for quotation of securities - DXB

05/06/25

493

05/06/25

Last post

ASX News

493

DXB Medicine

DXB Media thread.

6 7 8

05/06/25

439

230K

05/06/25

Last post Wasabi193

439

230K

DXB

DXB Chart

37 38 39

05/06/25

2.3K

971K

05/06/25

Last post BuffettWarren

2.3K

971K

DXB

Ann: 1st ACTION3 site in Japan activated and milestone triggered

04/06/25

10K

04/06/25

Last post Dr Evil Porkchop

10K

DXB

Ann: Application for quotation of securities - DXB

03/06/25

477

03/06/25

Last post

ASX News

477

DXB

Ann: Notification of upcoming expiry of Listed Options

02/06/25

5.0K

02/06/25

Last post Eqz

5.0K

DXB

Dimerix launches key trial in Japan as recruitment kicks off

30/05/25

240

30/05/25

Last post ASX Insights

240

DXB

Ann: Application for quotation of securities - DXB

29/05/25

427

29/05/25

Last post

ASX News

427

See All Discussions

Timeline

Application for quotation of securities - DXB
05 Jun 15:47	Share

Application for quotation of securities - DXB
03 Jun 11:38	Share

1st ACTION3 site in Japan activated and milestone triggered
30 May 08:26	Share

Application for quotation of securities - DXB
29 May 13:28	Share

Notification of upcoming expiry of Listed Options
29 May 09:25	Share

Application for quotation of securities - DXB
27 May 14:02	Share

Application for quotation of securities - DXB
22 May 11:53	Share

Successful planned IDMC review of ACTION3 trial
22 May 08:31	Share

Change in substantial holding
20 May 13:07	Share

Application for quotation of securities - DXB
20 May 13:06	Share

Dimerix to present at Melbourne Twilight Investor Briefing
20 May 09:33	Share

Application for quotation of securities - DXB
16 May 11:31	Share

Application for quotation of securities - DXB
14 May 12:58	Share

Application for quotation of securities - DXB
12 May 13:09	Share

Application for quotation of securities - DXB
08 May 15:19	Share

Dimerix receives initial upfront payment from Amicus
06 May 08:27	Share

Application for quotation of securities - DXB
01 May 14:20	Share

Investor Webinar and Presentation
01 May 09:22	Share

Dimerix Licenses DMX-200 in the US
01 May 09:10	Share

Quarterly Appendix 4C and Activities Report
30 Apr 12:01	Share

Trading Halt
29 Apr 08:31	Share

Application for quotation of securities - DXB
28 Apr 14:43	Share

FDA confirms Proteinuria as Primary Endpoint for US approval
28 Apr 08:32	Share

Application for quotation of securities - DXB
22 Apr 13:45	Share

Application for quotation of securities - DXB
16 Apr 14:54	Share

Dimerix to Present at ASX CEO Connect
15 Apr 08:24	Share

Application for quotation of securities - DXB
10 Apr 13:58	Share

Securities Trading Policy Update
08 Apr 08:25	Share

Application for quotation of securities - DXB
04 Apr 11:47	Share

Application for quotation of securities - DXB
02 Apr 14:13	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 56.0¢		Change -0.005(0.88%)		Mkt cap ! $327.6M

Open	High	Low	Value	Volume
57.0¢	57.0¢	55.0¢	$922.7K	1.651M

Buyers (Bids)

No.	Vol.	Price($)
2	304100	55.5¢

Sellers (Offers)

Price($)	Vol.	No.
56.0¢	92574	3

View Market Depth

No.	Vol.	Price($)
2	304100	0.555
24	294145	0.550
2	31833	0.545
6	66369	0.540
6	156000	0.535

Price($)	Vol.	No.
0.560	83794	2
0.565	100000	2
0.570	21506	2
0.585	40000	2
0.590	76776	3

Last trade - 16.10pm 06/06/2025 (20 minute delay)

DXB (ASX) Chart

DIMERIX LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Dimerix (ASX:DXB) to pocket $2.8m in R&D tax incentive prepayment

17 Feb 2023 10:56 (AEDT)

Dimerix (ASX:DXB) receives FDA approval to include teenagers in kidney disease study

12 Jan 2023 09:16 (AEDT)

Latest Articles

Dimerix launches key trial in Japan as recruitment kicks off

Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking to treat inflammatory diseases.

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

Dimerix has received the first multi-million dollar payment from its Japanese partner FUSO and expects those to continue.

Dimerix signs up first patient for 'highly significant' paediatric clinical trial

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research.The trial will investigate the efficacy of DMX-200 in children aged 12 to 17 with focal seg...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News